ECSP21071644A - Compuestos macrocíclicos como agonistas de sting - Google Patents

Compuestos macrocíclicos como agonistas de sting

Info

Publication number
ECSP21071644A
ECSP21071644A ECSENADI202171644A ECDI202171644A ECSP21071644A EC SP21071644 A ECSP21071644 A EC SP21071644A EC SENADI202171644 A ECSENADI202171644 A EC SENADI202171644A EC DI202171644 A ECDI202171644 A EC DI202171644A EC SP21071644 A ECSP21071644 A EC SP21071644A
Authority
EC
Ecuador
Prior art keywords
macrocyclic compounds
sting agonists
compounds
disclosed
macrocyclic
Prior art date
Application number
ECSENADI202171644A
Other languages
English (en)
Inventor
Moloy Banerjee
Vinod Vyavahare
Vidya Ramdas
Vaibhav Kalhapure
Navnath Karche
Pradeep Patil
Venkata Palle
Deepak Walke
Rajender Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of ECSP21071644A publication Critical patent/ECSP21071644A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se desvelan compuestos macrocíclicos que tienen la Fórmula general (I) y sus formas tautoméricas, estereoisómeros, sales farmacéuticamente aceptables y su combinación con un medicamento adecuado, procesos correspondientes para la síntesis, y composiciones farmacéuticas y usos de compuestos desvelados en el presente documento.
ECSENADI202171644A 2019-03-28 2021-09-24 Compuestos macrocíclicos como agonistas de sting ECSP21071644A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921012258 2019-03-28
IN201921046194 2019-11-13

Publications (1)

Publication Number Publication Date
ECSP21071644A true ECSP21071644A (es) 2021-12-30

Family

ID=70293003

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202171644A ECSP21071644A (es) 2019-03-28 2021-09-24 Compuestos macrocíclicos como agonistas de sting

Country Status (19)

Country Link
US (1) US20220144852A1 (es)
EP (1) EP3946610A1 (es)
JP (1) JP7530380B2 (es)
KR (1) KR20210146370A (es)
CN (1) CN113631228B (es)
AU (1) AU2020245263A1 (es)
BR (1) BR112021018947A2 (es)
CA (1) CA3132508A1 (es)
CL (1) CL2021002480A1 (es)
CO (1) CO2021012559A2 (es)
CR (1) CR20210495A (es)
EC (1) ECSP21071644A (es)
IL (1) IL286526A (es)
MA (1) MA55517A (es)
MX (1) MX2021011686A (es)
PE (1) PE20220169A1 (es)
SG (1) SG11202109191SA (es)
WO (1) WO2020194160A1 (es)
ZA (1) ZA202106629B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20247627B (en) * 2019-07-22 2024-05-27 Lupin Ltd Macrocyclic compounds as sting agonists and methods and uses thereof
KR20220056176A (ko) 2019-08-02 2022-05-04 메르사나 테라퓨틱스, 인코포레이티드 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
MX2023008327A (es) * 2021-01-15 2023-08-22 Seagen Inc Anticuerpos inmunomoduladores de anticuerpo-farmaco.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
SG11201704628VA (en) * 2015-02-05 2017-07-28 Merck Patent Gmbh Macrocyclic compounds as irak1/4 inhibitors and uses thereof
US10844051B2 (en) 2015-07-22 2020-11-24 The Royal Institution For The Advancement Of Learning/Mcgill University Substituted oxazoles for the treatment of cancer
AR107032A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
EA201892128A1 (ru) 2016-04-07 2019-04-30 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Гетероциклические амиды, полезные в качестве модуляторов
ES2921855T3 (es) * 2016-04-07 2022-09-01 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
US20200138827A1 (en) * 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
EP3642198B1 (en) 2017-06-22 2022-03-16 Curadev Pharma Limited Small molecule modulators of human sting
EP3642197A1 (en) 2017-06-22 2020-04-29 Curadev Pharma Limited Heterocyclic small molecule modulators of human sting
US10689376B2 (en) 2017-07-27 2020-06-23 Stingray Therapeutics, Inc. Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics
EP3661498A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
RU2020109328A (ru) * 2017-08-04 2021-09-06 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака

Also Published As

Publication number Publication date
ZA202106629B (en) 2022-07-27
PE20220169A1 (es) 2022-01-28
AU2020245263A1 (en) 2021-10-07
WO2020194160A1 (en) 2020-10-01
CA3132508A1 (en) 2020-10-01
CN113631228B (zh) 2023-10-13
KR20210146370A (ko) 2021-12-03
IL286526A (en) 2021-10-31
US20220144852A1 (en) 2022-05-12
CO2021012559A2 (es) 2021-09-30
JP2022527306A (ja) 2022-06-01
BR112021018947A2 (pt) 2022-02-08
EP3946610A1 (en) 2022-02-09
MA55517A (fr) 2022-02-09
MX2021011686A (es) 2021-10-22
JP7530380B2 (ja) 2024-08-07
CL2021002480A1 (es) 2022-04-29
CN113631228A (zh) 2021-11-09
CR20210495A (es) 2021-10-18
SG11202109191SA (en) 2021-09-29

Similar Documents

Publication Publication Date Title
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
ECSP21071644A (es) Compuestos macrocíclicos como agonistas de sting
CO2022001814A2 (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
BR112017024917A2 (pt) síntese de compostos heterocíclicos
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
CU20130139A7 (es) Derivados glocósidos y usos de los mismos
NI201900077A (es) Inhibidores selectivos de jak1
CL2019001481A1 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos.
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CO2021007442A2 (es) Compuesto de 1,3,4-oxadiazolona y fármaco
CL2017000582A1 (es) Nuevos compuestos derivados de piridopirimidinas
TH1801001086A (th) นิวคลีโอไซด์อะนาล็อกที่ถูกแทนที่ด้วยวง 6-6 ไบไซคลิกอะโรมาติกชนิดใหม่สำหรับใช้เป็นตัวยับยั้ง prmt5
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos